Walgreens Boots Alliance is in the process of selling its stake in VillageMD, a doctor-staffed clinic operator that has proven to be a costly investment for the drugstore giant. The decision to divest from VillageMD comes after years of significant financial losses and a strategic shift towards more profitable ventures to revive the struggling drugstore chain.
To facilitate the sale, Walgreens has enlisted the expertise of investment banking firm Evercore and consulting firm Alvarez & Marsal as advisors. The company’s CEO, Tim Wentworth, has been vocal about the need to reduce the investment in VillageMD and focus on improving the overall financial health of the organization. Wentworth stated during a recent earnings call that the process of exiting VillageMD has already begun.
Under former CEO Roz Brewer, Walgreens made a substantial investment of over $6 billion in VillageMD to acquire a controlling stake in the company. However, the expansion of doctor practices and clinics attached to Walgreens has been scaled back significantly in light of ongoing challenges. Despite ambitious plans to open hundreds of primary care clinics under the “Village Medical at Walgreens” brand, the company has faced difficulties in attracting enough patients to fill their provider panels.
The financial impact of the VillageMD investment has been substantial, with Walgreens reporting operating losses exceeding $13 billion for the first nine months of fiscal 2024. A significant non-cash impairment charge related to VillageMD goodwill accounted for a substantial portion of these losses. In response to these challenges, VillageMD CEO Tim Barry departed the company, and Jim Murray took on the role of interim CEO.
As Walgreens navigates the process of selling its stake in VillageMD, the outcome remains uncertain. The company’s U.S. Healthcare segment, which includes VillageMD, urgent care provider CityMD, primary care provider Summit Health, and the CareCentrix home care business, saw improved sales performance in the first quarter. This growth contributed to a narrowing of operating losses in the segment compared to the previous year.
The decision to sell its stake in VillageMD reflects Walgreens’ commitment to reshaping its business strategy and focusing on initiatives that drive sustainable growth. By divesting from VillageMD and reallocating resources to more promising opportunities, Walgreens aims to strengthen its financial position and position itself for long-term success in the competitive healthcare industry.
